Comparison of ciclesonide 160 μg/d with budesonide 400 μg/d in a randomised, double-blind study in children with moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 711s Year: 2006
Budesonide versus prednisone in acute wheezing: randomized double-blinded controlled placebo study Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives Year: 2008
Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Randomised, double-blind, double-dummy, parallel-group comparison of the effect of fluticasone propionate (FP) 100 μg bd and budesonide (BUD) 200 μg bd on childhood growth: protocol and baseline characteristics Source: Eur Respir J 2001; 18: Suppl. 33, 289s Year: 2001
Once daily ciclesonide (80 µg or 320 µg) is equally effective as budesonide 200 µg given twice daily: a 12-week study in asthma patients Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003
Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021
Efficacy and safety of indacaterol 150 μg once-daily in COPD: a 12-week study Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Open-label, randomized, comparative trail of the efficacy of the azithromycin in the 8-week treatment of mild-to-moderate asthma Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007
A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009
A multicenter, randomised, double-blind, placebo-controlled 6 month trial to evaluate efficacy and tolerability of bupropion hydrochloride sustained release (SR) tablets as treatment for nicotine dependency in healthcare workers and as an aid to smoking Source: Eur Respir J 2002; 20: Suppl. 38, 611s Year: 2002
Efficacy of a synbiotic supplementation in the prevention of respiratory and intestinal diseases in children: A randomized, double-blind placebo controlled study Source: Annual Congress 2010 - Childhood pneumonia: from prevention to complications Year: 2010
Efficacy of azithromycin in severe asthma from the AMAZES randomised trial Source: ERJ Open Res, 5 (4) 00056-2019; 10.1183/23120541.00056-2019 Year: 2019
Efficacy of a short course of oral prednisolone for acute preschool viral-wheeze: a double-blind randomised placebo-controlled trial with stratification for systemic eosinophil priming Source: Eur Respir J 2003; 22: Suppl. 45, 388s Year: 2003
The effect of high dose N-acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients — A double blinded randomized placebo controlled trial Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD Source: ERJ Open Res 2016: 00101-2015 Year: 2016
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial Source: Eur Respir J, 59 (1) 2100752; 10.1183/13993003.00752-2021 Year: 2022